About: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	BACKGROUND: Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic response and progression-free survival among patients with chronic myeloid leukemia (CML) in the chronic phase, after failure of imatinib treatment. We assessed the efficacy and safety of dasatinib, as compared with imatinib, for the first-line treatment of chronic-phase CML. METHODS: In a multinational study, 519 patients with newly diagnosed chronic-phase CML were randomly assigned to receive dasatinib at a dose of 100 mg once daily (259 patients) or imatinib at a dose of 400 mg once daily (260 patients). The primary end point was complete cytogenetic response by 12 months, confirmed on two consecutive assessments at least 28 days apart. Secondary end points, including major molecular response, were tested at a significance level of 0.0001 to adjust for multiple comparisons. BACKGROUND: Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic response and progression-free survival among patients with chronic myeloid leukemia (CML) in the chronic phase, after failure of imatinib treatment. We assessed the efficacy and safety of dasatinib, as compared with imatinib, for the first-line treatment of chronic-phase CML. METHODS: In a multinational study, 519 patients with newly diagnosed chronic-phase CML were randomly assigned to receive dasatinib at a dose of 100 mg once daily (259 patients) or imatinib at a dose of 400 mg once daily (260 patients). The primary end point was complete cytogenetic response by 12 months, confirmed on two consecutive assessments at least 28 days apart. Secondary end points, including major molecular response, were tested at a significance level of 0.0001 to adjust for multiple comparisons. (en)
Title	Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. (en)
skos:prefLabel	Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. (en)
skos:notation	RIV/00216224:14110/10:00051394!RIV12-MSM-14110___
http://linked.open...avai/riv/aktivita	V
http://linked.open...avai/riv/aktivity	V
http://linked.open...iv/cisloPeriodika	24
http://linked.open...vai/riv/dodaniDat	2012
http://linked.open...aciTvurceVysledku	Mayer, Jiří
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Lékařská fakulta
http://linked.open...dnocenehoVysledku	252924
http://linked.open...ai/riv/idVysledku	RIV/00216224:14110/10:00051394
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	CHRONIC MYELOGENOUS LEUKEMIA; KINASE DOMAIN MUTATIONS; DURABLE CYTOGENETIC RESPONSES; PATIENTS RECEIVING IMATINIB; BCR-ABL; INTERFERON-ALPHA; FOLLOW-UP; MOLECULAR RESPONSE; RESISTANCE; SURVIVAL (en)
http://linked.open.../riv/klicoveSlovo	FOLLOW-UP CHRONIC MYELOGENOUS LEUKEMIA PATIENTS RECEIVING IMATINIB BCR-ABL RESISTANCE SURVIVAL DURABLE CYTOGENETIC RESPONSES INTERFERON-ALPHA KINASE DOMAIN MUTATIONS MOLECULAR RESPONSE
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[75A039AE0E17]
http://linked.open...i/riv/nazevZdroje	The New England Journal of Medicine
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	20 (xsd:int)
http://linked.open...UplatneniVysledku	2010
http://linked.open...v/svazekPeriodika	362
http://linked.open...iv/tvurceVysledku	Mayer, Jiří Kantarjian, Hagop Ayala, Manuel Baccarani, Michele Bleickardt, Eric Boqué, Concepcion Bradley-Garelik, M. Brigid Chuah, Charles Cortes, Jorge Hochhaus, Andreas Huguet, Francoise Moiraghi, Beatriz Nakamae, Hirohisa Pasquini, Ricardo Shah, Neil P. Shah, Sandip Shapiro, David Shen, Zhixiang Szatrowski, Ted Zhu, Chao
http://linked.open...ain/vavai/riv/wos	000278816300005
issn	0028-4793
number of pages	11 (xsd:int)
http://bibframe.org/vocab/doi	10.1056/NEJMoa1002315
http://localhost/t...ganizacniJednotka	14110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software